Pharmafile Logo
Pharmafocus logo
Advanced Search

NICE

Showing 15 posts of 857 posts found.

NICE recommends new triple therapy for multiple myeloma patients

March 19, 2021
Medical Communications NHS England, NICE, oncology

A new second line triple therapy is to be offered to NHS patients in England with multiple myeloma, following a …

News

AstraZeneca & MSD ovarian cancer drug combination approved by NICE

March 19, 2021
Medical Communications AstraZeneca, MSD, NICE, oncology

A new precision drug combination, olaparib with bevacizumab, will now be available on the Cancer Drugs Fund (CDF) for ovarian …

News
index_ph001

NICE recommends Daiichi Sankyo’s cholesterol-lowering treatments for NHS England use

March 18, 2021
Daiichi Sankyo, NICE, cholesterol

NICE has recommended Daiichi Sankyo’s bempedoic acid and bempedoic acid/ezetimibe for treating primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed …

News

NICE recommends £1.79m gene therapy for spinal muscular atrophy in babies

March 8, 2021
Sales and Marketing NICE, spinal muscular atrophy

NICE is set to approve a new and potentially curative one-off gene therapy for babies with the rare genetic disorder …

News

NICE recommends Novartis’ ribociclib in combination with fulvestrant for breast cancer

February 26, 2021
Medical Communications Cancer, NICE, Novartis

NICE has recommended Novartis’ Kisqali (ribociclib) in combination with fulvestrant for women with prior endocrine therapy. It will be made …

News

NICE issues draft guidance recommending sapropterin for PKU in children

February 25, 2021
BioMarin, NICE, PKU

NICE has issued draft guidance which recommends BioMarin’s Kuvan (sapropterin) at a dose of up to 10 mg/kg for treating phenylketonuria …

News
opdivo_1_1

NICE recommends Bristol Myers Squibb’s skin cancer drug Opdivo for NHS use

February 12, 2021
Medical Communications Bristol-Myers Squibb, NICE, bristol myers squibb

NICE has issued final draft guidance recommending the routine use of Bristol Myers Squibb (BMS)’s Opdivo (nivolumab) as an option …

News

NICE recommends treatments for pregnancy sickness in new draft guidance

February 11, 2021
NICE, Pregnant

NICE has recommended treatment options for severe pregnancy sickness for the first time, issuing recommendations in draft guidance published today.

News

NICE rejects multiple sclerosis drug Zeposia

January 22, 2021
Medical Communications NICE

NICE has decided not to recommend Bristol Myers Squibb’s Zeposia (ozanimod) for the treatment of relapsing/remitting multiple sclerosis (RRMS). In …

News
gilead-sciences

NICE recommends rheumatoid arthritis drug Jyseleca for NHS use

January 21, 2021
Gilead, NICE

NICE has issued a final appraisal determination (FAD) recommending the use of Jyseleca (filgotinib) on the NHS in England for …

News

NICE approves lipid disorder drug Myalepta for NHS use

January 20, 2021
Research and Development Amryt Pharma, NICE

NICE has approved Amryt’s rare lipid disorder drug Myalepta (metreleptin), currently the only leptin replacement therapy available, for use within …

News

NICE recommends cutting-edge lymphoma treatment for NHS use

January 19, 2021
Manufacturing and Production Cancer, NICE

NHS clinicians in England will be able to consider a cutting-edge cancer treatment for some patients with a form of …

News

NICE recommends GSK’s ZEJULA for advanced ovarian cancer

January 15, 2021
Medical Communications Cancer, GlaxoSmithKline, NICE

NICE has recommended the use of GlaxoSmithKline’s ZEJULA (niraparib) on the NHS in England for adult women with advanced high-grade …

News

NICE recommends AstraZeneca’s FORXIGA for heart failure

January 7, 2021
AstraZeneca, NICE

NICE has issued a positive Final Appraisal Document (FAD) recommending AstraZeneca’s FORXIGA (dapagliflozin) as an option for treatment of symptomatic …

News

Shionogi’s novel antibiotic selected for UK pilot subscription reimbursement model

December 21, 2020
Sales and Marketing NICE, Shionogi, antibiotic

Japanese pharmaceutical company Shionogi today announced that NICE and NHS England and Improvement (NHSE&I) have selected its novel antibiotic Fetcroja …

News

Latest content

AbbVie invests €150m in new R&D facility in Germany

May 3, 2024

AstraZeneca shares positive interim results from phase 3 lymphoma trial

May 3, 2024

Merck shares data from phase 3 trial of Keytruda for gastric cancers

May 2, 2024

Verona Pharma to share phase 3 COPD trial data at ATS 2024

May 2, 2024

Beckman Coulter Life Sciences and Watchmaker Genomics enter collaboration

May 1, 2024